Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tubulis

Request full access

Generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology

Planegg, GermanyFounded 2019Biotech & Life Sciences

About Tubulis

Tubulis is a biotechnology startup that operates in the pharmaceutical industry, specifically in the development of next-generation Antibody-Drug Conjugates (ADCs). These are targeted drugs designed to deliver cytotoxic agents directly to cancer cells, thereby increasing the effectiveness of treatment while reducing side effects. Tubulis' unique approach aims to expand the therapeutic potential of these protein-drug conjugates by increasing design flexibility and overcoming constraints of toxicity, efficacy, and indication.

The company's business model revolves around the development of new ADCs to fill its pipeline and partnering with other pharmaceutical companies to bring these drugs to market. One of its key partnerships is with Oncoteq, for the development of TUB-010, a CD30-targeting ADC. Tubulis has also entered into a strategic license agreement with Bristol Myers Squibb, a leading pharmaceutical company, to develop next-generation ADCs for cancer treatment.

Tubulis generates revenue through these strategic partnerships and licensing agreements, where it receives upfront payments, milestone payments based on the progress of drug development, and potential royalties from the sale of any approved drugs. The company also publishes research articles, such as the one in Molecular Cancer Therapeutics, highlighting the advantages of its proprietary P5/Tubutecan platform.

The company's primary clients are other pharmaceutical and biotechnology companies interested in developing and commercializing novel ADCs. By offering a unique and flexible approach to ADC design, Tubulis is well-positioned to serve a significant market need in the oncology drug development space.

Source: Dealroom company data

Tubulis in the Planegg ecosystem

Live from Dealroom

The Tubulis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

25 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • Seventure Partners
  • Coparion
  • HTGF
  • BioMedVC
  • Bayern Kapital
  • OCCIDENT
  • Evotec
  • Andera Partners
  • FundPlus
  • Deep Track Capital
  • Frazier Life Sciences
  • EQT Life Sciences
  • Nextech Invest

Series B and later12 investors entered at this stage

  • Nextech
  • ZweiKa Holding
  • Greendale Holding
  • South Lake Holding
  • EQT Ventures
  • Fund+
  • Science Holding
  • HSM Holding
  • LeXito
  • Venrock
  • Wellington Management
  • Ascenta Capital
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$606k

13 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Tubulis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.